Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 351–400 of 563 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT01739439	Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance…	Phase 1	terminated	Dec 3, 2012	Fox Chase Cancer Center	Slow accrual	Enrollment / accrual
NCT01314027	Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer	Phase 3	terminated	Mar 14, 2011	University of Zurich	low recruitment	Enrollment / accrual
NCT02404363	Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL)	Phase 3	terminated	Mar 31, 2015	Assistance Publique - Hôpitaux de Paris	recruitment problem	Enrollment / accrual
NCT03778879	Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or…	Phase 1 / Phase 2	withdrawn	Dec 19, 2018	Alan Katz	CCX872-B will not be available in sufficient quantity to conduct the study.	Other (stated, no rule matched)
NCT02124369	Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE)	Phase 2	terminated	Apr 28, 2014	CCTU- Cancer Theme	Poor accrual	Enrollment / accrual
NCT01313416	Gemcitabine and CT-011 for Resected Pancreatic Cancer	Phase 2	terminated	Mar 11, 2011	Augusta University	Drug supply issues	Drug supply
NCT02205788	Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic…	—	withdrawn	Jul 31, 2014	Patrick Joseph Loehrer Sr.	not stated	Not stated
NCT02736578	Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients…	Phase 2	terminated	Apr 13, 2016	Eben Rosenthal	Logistics	Other (stated, no rule matched)
NCT03697239	High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +…	Phase 1 / Phase 2	withdrawn	Oct 5, 2018	Hitendra Patel	FDA indicated the same study could not be conducted under multiple INDs	Other (stated, no rule matched)
NCT03797443	High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +…	Phase 1 / Phase 2	withdrawn	Jan 9, 2019	Piedmont Cancer Institute	Regulatory Review needed	Other (stated, no rule matched)
NCT03432676	Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer	Phase 2	withdrawn	Feb 14, 2018	M.D. Anderson Cancer Center	Incyte (supporter of the study) is no longer going to support the study.	Other (stated, no rule matched)
NCT03908333	High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and…	Phase 1 / Phase 2	withdrawn	Apr 9, 2019	Medical College of Wisconsin	Request to close per funding sponsor. Site not moving forward with trial.	Funding
NCT03392571	Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients	Phase 2	withdrawn	Jan 8, 2018	Pancreatic Cancer Research Team	Study was stopped due to lack of funding	Funding
NCT01276613	Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the…	Early Phase 1	terminated	Jan 13, 2011	M.D. Anderson Cancer Center	Per memo from study team	Other (stated, no rule matched)
NCT02581501	Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer	Phase 1	withdrawn	Oct 21, 2015	Stamford Hospital	Due to no enrollment, Celgene (sponsor) withdrew funding	Enrollment / accrual
NCT00968604	C-VISA BikDD: Liposome in Advanced Pancreatic Cancer	Phase 1	withdrawn	Aug 31, 2009	M.D. Anderson Cancer Center	Stability of the DNA when admixed with the liposome failed	Other (stated, no rule matched)
NCT02868632	Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable,…	Phase 1	withdrawn	Aug 16, 2016	NYU Langone Health	termination because of low accrual; four subjects enrolled and four screen failures.	Enrollment / accrual
NCT02950025	Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary…	Phase 2	terminated	Oct 31, 2016	Washington University School of Medicine	Low accrual	Enrollment / accrual
NCT02117479	Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)	Phase 3	terminated	Apr 21, 2014	Incyte Corporation	The study was terminated early based on the results of the planned interim analysis.	Efficacy / futility
NCT01569282	Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer	N/A	withdrawn	Apr 3, 2012	Göteborg University	Difficulties to recruit patients	Enrollment / accrual
NCT02782182	Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot…	Phase 1	terminated	May 25, 2016	University of Chicago	Closed early due to poor accrual.	Enrollment / accrual
NCT01760252	Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol	Phase 2	terminated	Jan 4, 2013	Beth Israel Medical Center	not stated	Not stated
NCT01484860	Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line…	Phase 2	terminated	Dec 2, 2011	University Health Network, Toronto	not stated	Not stated
NCT01025882	Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer	Phase 1	terminated	Dec 4, 2009	University of Texas Southwestern Medical Center	DSMC closed due to patient deaths	Other (stated, no rule matched)
NCT02548169	Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer(PancVax)	Phase 1	terminated	Sep 14, 2015	Baylor Research Institute	The study was stopped because of loss of funding and no safety issues	Safety / toxicity
NCT02570529	Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally…	Phase 4	withdrawn	Oct 7, 2015	Yonsei University	Investigator decided to stop the study because it was difficult to proceed with the study.	Investigator
NCT00364364	Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best…	Early Phase 1	terminated	Aug 15, 2006	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Loss of funding	Funding
NCT01632306	A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer	Phase 1 / Phase 2	terminated	Jul 2, 2012	Eli Lilly and Company	Study has been terminated due to slow enrollment.	Enrollment / accrual
NCT03225781	Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer	N/A	terminated	Jul 21, 2017	Universita di Verona	Logistic reasons	Other (stated, no rule matched)
NCT00310050	Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced…	Phase 1	terminated	Apr 3, 2006	Wake Forest University Health Sciences	slow accrual	Enrollment / accrual
NCT00867126	Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment…	Early Phase 1	terminated	Mar 23, 2009	University of Texas Southwestern Medical Center	low accrual	Enrollment / accrual
NCT02442739	Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or…	Early Phase 1	withdrawn	May 13, 2015	Cedars-Sinai Medical Center	PI voluntary closure due to low accrual	Enrollment / accrual
NCT02669914	MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2	terminated	Feb 1, 2016	Washington University School of Medicine	Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice	Enrollment / accrual
NCT00276744	Individualized Drug Treatment for Treating Patients With Pancreatic Cancer	Phase 2	terminated	Jan 13, 2006	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Because there was no longer an active laboratory component to this study.	Other (stated, no rule matched)
NCT00868114	Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer	Phase 2	terminated	Mar 24, 2009	Leo W. Jenkins Cancer Center	Poor recruitment	Enrollment / accrual
NCT02967770	Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic…(PanCAN)	Phase 2	withdrawn	Nov 18, 2016	Georgetown University	Issues with patient recruitment.	Enrollment / accrual
NCT00783172	Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer	Phase 1	terminated	Oct 31, 2008	Milton S. Hershey Medical Center	Problems with IRB	Other (stated, no rule matched)
NCT02650635	TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,…	Phase 1	terminated	Jan 8, 2016	Mayo Clinic	permanently closed per sponsor's request	Other (stated, no rule matched)
NCT01621243	M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer	Phase 1 / Phase 2	terminated	Jun 18, 2012	Momenta Pharmaceuticals, Inc.	The study was terminated after a pre-planned futility analyses showed an insufficient level of…	Efficacy / futility
NCT02241551	Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and…	Phase 2	terminated	Sep 16, 2014	Nathan Bahary, MD	Study was terminated with the IRB ended early as logistical concerns of the SBRT	Other (stated, no rule matched)
NCT03073473	Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers	—	terminated	Mar 8, 2017	Cota Inc.	Poor accrual	Enrollment / accrual
NCT01921751	High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and…	Phase 2	terminated	Aug 13, 2013	Radiation Therapy Oncology Group	Trial would not be completed in a reasonable timeframe per CTEP guidelines	Other (stated, no rule matched)
NCT02345460	Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2	terminated	Jan 26, 2015	Case Comprehensive Cancer Center	Competing studies	Other (stated, no rule matched)
NCT00386399	Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With…	Phase 2	withdrawn	Oct 11, 2006	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All consented subjects tested negative for the BRCA2 mutation, therefore, did not meet criteria to…	Other (stated, no rule matched)
NCT02767752	Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With…(CHIPAC)	Phase 2	terminated	May 10, 2016	Herlev Hospital	Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)	Enrollment / accrual
NCT02331251	Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)	Phase 1 / Phase 2	terminated	Jan 6, 2015	Western Regional Medical Center	PI not longer at site.	Other (stated, no rule matched)
NCT02423954	Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus)	Phase 1 / Phase 2	terminated	Apr 22, 2015	Western Regional Medical Center	Investigator no longer at site to enroll patients or write up data	Investigator
NCT01795274	Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic…(PHOENIX-01)	N/A	withdrawn	Feb 20, 2013	University Hospital Heidelberg	Administrative barriers	Other (stated, no rule matched)
NCT00889187	Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for…	Phase 1 / Phase 2	terminated	Apr 28, 2009	Dana-Farber Cancer Institute	Excess toxicity was identified intraoperatively	Safety / toxicity
NCT01900327	Neoadjuvant Treatment in Resectable Pancreatic Cancer(NEOPA)	Phase 3	terminated	Jul 16, 2013	Universitätsklinikum Hamburg-Eppendorf	Recruitment failure	Enrollment / accrual

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Jul 29, 2019source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules